Helus Pharma (HELP) closed at $9.39 on November 11, 2026, up 3.5% from the previous close, on volume of 1,311,482 shares (30-day average 1,415,659).
Data as of November 11, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 21, 2026 | Call Spread | 18-Dec-2612.5 : 20 C | 10,014 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 11, 2026. See the 10 largest for 30, 60 and 90 days
U.S. funding to support studies into psychedelic drug ibogaine in PTSD
Seeking Alpha News (Thu, 12-Nov 12:47 PM ET)
DEA looks to increase legal psychedelics production for medical research
Seeking Alpha News (Tue, 10-Nov 10:45 AM ET)
J&J gets into psychedelic treatments with backing of Delix Therapeutics
Seeking Alpha News (Mon, 9-Nov 12:12 PM ET)
Analysts’ Top Healthcare Picks: Edwards Lifesciences (EW), Helus Pharma (HELP)
TipRanks (Mon, 9-Nov 11:20 AM ET)
Market Chameleon (Tue, 3-Nov 4:13 AM ET)
Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference
Globe Newswire (Tue, 3-Nov 7:30 AM ET)
Globe Newswire (Tue, 27-Oct 8:00 AM ET)
Globe Newswire (Wed, 21-Oct 4:10 PM ET)
Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors
Globe Newswire (Thu, 15-Oct 7:30 AM ET)
Helus Pharma to Host Investor Presentation on October 21, 2026
Globe Newswire (Thu, 8-Oct 7:30 AM ET)
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
Helus Pharma trades on the NASDAQ stock market under the symbol HELP.
As of November 12, 2026, HELP stock price declined to $8.88 with 452,977 million shares trading.
HELP has a beta of 2.48, meaning it tends to be more sensitive to market movements. HELP has a correlation of 0.13 to the broad based SPY ETF.
HELP has a market cap of $648.77 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that HELP belongs to (by Net Assets): PSIL, ONEQ, GWX, QQQS.
HELP support price is $8.90 and resistance is $9.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HELP shares will trade within this expected range on the day.
